Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?

Table 3

Characteristics of novel oral anticoagulants.

Agent	Trade name	Target	Bioavailability (%)	Time to peak; concentration (h)	Half-Life (h)	Excretion	Dosing; frequency	Drug; interactions	Contraindications	Monitoring?
Dabigatran	Pradaxa	IIa	3–7	2-3	12–14	Urine (80%); Biliary (20%)	BID	P-glycoprotein	CrCl < 30 mL/min	No
Rivaroxaban	Xarelto	Xa	80	2.4–4	5–9	Urine (66%), Biliary (28%)	Daily	CYP-3A4	CrCl < 30 mL/min Hemodialysis; Child-Pugh B, C	No
Apixaban	Eliquis	Xa	50	3	8–15	Urine (25%)	Daily	CYP-3A4; P-glycoprotein	CrCl < 15 mL/min	No